List of Abilify drug patents
Abilify is owned by Otsuka.
Abilify contains Aripiprazole.
Abilify has a total of 20 drug patents out of which 9 drug patents have expired.
Expired drug patents of Abilify are:
- US8642600
- US9089567
- US7053092
- US6977257
- US8642600*PED
- US6977257*PED
- US9359302
- US8580796
- US8642760
Abilify was authorised for market use on 07 June, 2006.
Abilify is available in tablet, orally disintegrating;oral dosage forms.
Abilify can be used as treatment of major depressive disorder (mdd), treatment of irritability associated with autistic disorder, acute treatment of manic and mixed episodes associated with bipolar i disorder, treatment of schizophrenia, adjunctive treatment of major depressive disorder (mdd), treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar i disorder, adjunctive treatment of major depressive disorder, and treatment of irritability associated with autistic disorder.
The generics of Abilify are possible to be released after 02 March, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642600 | OTSUKA | Method of treating autism |
Jan, 2022
(1 year, 1 day ago) | |
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(1 year, 1 day ago) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(1 year, 1 day ago) | |
| US6977257 | OTSUKA | Aripiprazole oral solution |
Apr, 2022
(9 months ago) | |
|
US8642600
(Pediatric) | OTSUKA | Method of treating autism |
Jul, 2022
(6 months ago) | |
|
US6977257
(Pediatric) | OTSUKA | Aripiprazole oral solution |
Oct, 2022
(3 months ago) | |
|
US8580796
(Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(a month from now) | |
|
US8642760
(Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(a month from now) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(10 months from now) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(1 year, 4 months from now) | |
| US7115587 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(1 year, 5 months from now) | |
| US7550445 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(1 year, 5 months from now) | |
|
US8017615
(Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(1 year, 10 months from now) | |
|
US7115587
(Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(1 year, 11 months from now) | |
|
US7550445
(Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(1 year, 11 months from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(3 years from now) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(4 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 07 June, 2006
Treatment: Treatment of irritability associated with autistic disorder; Treatment of schizophrenia; Treatment of major depressive disorder (mdd); Adjunctive treatment of major depressive disorder (mdd); Acute treatment of manic and mixed episodes associated with bipolar i disorder; Treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar i disorder, adjunctive treatment of major depressive disorder, and treatment of irritability associated with autistic disorder
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic